A Phase III clinical trial found that nicotinamide riboside, an NAD-boosting supplement, did not slow Parkinson’s disease.

Statin use was associated with a lower risk of open-angle glaucoma and less need for surgery, laser treatment, and ...

An analysis of multiple cancer types has revealed mitochondrial DNA copy number as a key determinant of mutational load and ...

A single tRNA can influence whether prostate cancer cells mutate and become difficult to treat with standard therapies.

A short peptide reduced chronic pain-like behaviors in mice without disrupting the acute pain signals that help protect ...

The way people speak may reveal important clues about their brain health and point to early signs of cognitive decline.

Kodiak's eye drug Zenkuda edges towards approval after another successful Phase III trial in wet AMD adds to other successful ...

Amylin-based petrelintide has achieved good results at Phase II for obesity, showing 8-11% weight loss and a good side effect profile.

Simultaneously reprogramming immune cells and strengthening T cells can make glioblastoma tumors shrink and prevent ...

By targeting GIP, GLP-1, and glucagon receptors, the investigational triple agonist could mark the next evolution in incretin ...

Researchers have identified a previously unrecognized protective role for the brain’s immune cells in people with Parkinson’s disease.

Chemotherapy could make cancer vaccines more effective, and adding PD-1 blockade to the mix could be even better, according to new research from the Oxford Branch of the Ludwig Institute for Cancer ...